Zoetis Earnings Call: Growth Holds Amid Competitive Strain

Zoetis ((ZTS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Zoetis’ latest earnings call painted a picture of a company delivering disciplined growth while navigating real competitive and market headwinds. Management emphasized solid organic revenue and earnings expansion, better margins, and strong franchises like Simparica and diagnostics, but also acknowledged pressure in osteoarthritis pain products, U.S. clinic traffic, and promotional battles in key categories.

Steady Top-Line Growth Led by Pricing Power

Zoetis reported full-year revenue of $9.5 billion, up 2% on a reported basis and 6% organically, with roughly 4% from price and 2% from volume. This balance shows the company still has pricing power across its portfolio, even as certain markets soften and competition intensifies in select product lines.

Earnings and EPS Advance Faster Than Sales

Adjusted net income reached $2.8 billion, growing 6% reported and 7% on an organic operational basis, outpacing revenue growth. Adjusted diluted EPS rose around 6% operationally and 10% on an organic operational basis, underscoring effective cost control and capital deployment that are supporting shareholder returns.

Simparica and Trio Remain Core Growth Engines

The Simparica franchise delivered $1.5 billion in annual revenue, up 12% operationally and cementing its status as a cornerstone of Zoetis’ companion animal business. Simparica Trio crossed the $1 billion mark in U.S. sales, with global operational growth of 13% and about 10% growth in the U.S., helping offset weakness in other categories.

Diagnostics Business Outperforms the Market

Companion Animal Diagnostics grew 13% operationally for the year and 10% in the fourth quarter, a clear outperformance relative to overall company growth. U.S. diagnostics rose 14%, fueled by new platforms like VetScan Optocell and expanded use of the AI-enabled Imagyst system, which are deepening Zoetis’ presence in clinics.

Livestock Portfolio Delivers Broad-Based Momentum

Livestock revenue reached $2.8 billion, up 8% on an organic operational basis for the year, with international livestock advancing 10%. Growth was broad-based, with strong contributions from poultry, aquaculture products such as Moritella, cattle solutions, and vaccines, underscoring the resilience of Zoetis’ diversified livestock platform.

Margins Expand with FX Tailwind and Portfolio Mix

Full-year adjusted gross margin expanded to 71.9%, up 120 basis points on a reported basis, aided by about 80 basis points from foreign exchange. Additional margin gains came from pricing and the divestiture of the MFA business, which shifted mix toward higher-margin offerings and helped fund continued investment in growth.

Robust Capital Returns and Financial Flexibility

Zoetis returned more than $3.2 billion through share repurchases and $800 million in dividends in 2025, signaling confidence in its long-term outlook. The company also completed a convertible bond that helped support a $1.75 billion buyback while preserving balance sheet capacity for strategic investments and pipeline development.

U.S. Pet Owners Show Price Sensitivity

Management flagged ongoing economic pressure on Gen Z and millennial pet owners, which has led to declines in therapeutic visits and doses. Routine veterinary care has become more price-sensitive, pressuring volumes and amplifying the impact of competitive promotions across several companion animal categories.

Dermatology and Parasiticides Face Intensifying Competition

Dermatology growth decelerated as new entrants and elevated launch promotions hit the category, with key dermatology products up 6% for the year but only 1% in the fourth quarter. Parasiticides also saw heavier promotional intensity, as rivals aggressively targeted share, forcing Zoetis to compete more on price and incentives.

OA Pain Franchise Becomes a Major Headwind

The osteoarthritis pain monoclonal antibody franchise posted a 3% operational decline to $568 million for the year, turning into a material drag on companion animal performance. Librela fell 6% operationally, with U.S. Librela sales down about 16% for the year and roughly 32% in the fourth quarter, contributing to an 11% Q4 decline in overall OA pain revenue.

One-Time International Timing Boost Distorts Q4

Operational changes tied to fiscal-year alignment pulled some international demand into the fourth quarter of 2025, boosting that segment’s Q4 growth by roughly 2.5%–3.5%. Management stressed that this timing benefit, equivalent to around 30–40 basis points for the total company, is nonrecurring and complicates quarter-to-quarter comparisons.

Flat U.S. Revenue Highlights Domestic Softness

U.S. segment revenue was flat at $5.1 billion on a reported basis for the year, with localized declines in companion animal weighing on performance. Fourth-quarter U.S. OA mAb revenue fell about 25%, further pressuring near-term domestic growth and underscoring Zoetis’ reliance on other franchises and international markets for momentum.

Manufacturing Costs Weigh on First-Half Margins

Higher manufacturing costs tied to inventory valued at prior-year standards offset some of the margin benefit from pricing and the MFA divestiture in the first half. These cost pressures are expected to ease over time as newer, more favorable cost structures roll through inventory, but they were a notable temporary hurdle.

ERP and Fiscal Alignment Add Reporting Complexity

A multiyear ERP transition and planned fiscal-year alignment are introducing timing shifts that affect reported results, including delayed or accelerated orders and changes in price timing. These changes require recasting prior periods and add short-term complexity to interpreting trends, though management framed them as necessary infrastructure upgrades.

Competitive Uncertainty Shapes Near-Term Outlook

Zoetis anticipates heightened competitive intensity in 2026 for key dermatology and parasiticide categories, with more launches and sustained promotional activity. This environment has been baked into what management described as conservative guidance assumptions, reflecting realistic expectations rather than aggressive targets.

Guidance Signals Modest but Durable Growth

For 2026, Zoetis expects organic operational revenue growth of 3%–5% and organic operational adjusted net income growth of 3%–6%, implying reported revenue of $9.825–$10.025 billion and adjusted net income of $2.975–$3.025 billion. Adjusted diluted EPS is projected at $7.00–$7.10, including about $0.22 of benefit from recent buybacks, supported by stable cost ratios and balanced contributions from price and volume.

Zoetis’ earnings call suggested a company balancing strong underlying franchises with a cautious near-term stance shaped by competition and macro sensitivity. Investors will be watching how quickly OA pain trends stabilize, whether diagnostics and Simparica can keep offsetting pressures, and how effectively management navigates 2026’s promotional battles while preserving profitability and growth.